• Reference Citation Analysis
  • v
  • v
  • Find an Article
Find an Article PDF (4619801)   Today's Articles (70)   Subscriber (49403)
For: Abbas AA, Abdellattif MH, Dawood KM. Inhibitory activities of bipyrazoles: a patent review. Expert Opin Ther Pat 2021;32:63-87. [PMID: 34232805 DOI: 10.1080/13543776.2021.1953474] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Number Cited by Other Article(s)
1
Nafie MS, Kahwash SH, Youssef MM, Dawood KM. Recent advances on quinoxalines as target-oriented chemotherapeutic anticancer agents through apoptosis. Arch Pharm (Weinheim) 2024:e2400225. [PMID: 38822393 DOI: 10.1002/ardp.202400225] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/27/2024] [Revised: 05/06/2024] [Accepted: 05/07/2024] [Indexed: 06/03/2024]
2
Interactions of novel pyrazole ligand and its transition metal complexes with CT-DNA and BSA: a combination of experimental and computational studies. Polyhedron 2022. [DOI: 10.1016/j.poly.2022.116273] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
3
Biological activity evaluation of novel monoamine oxidase inhibitory compounds targeting Parkinson disease. Future Med Chem 2022;14:1663-1679. [PMID: 36317547 DOI: 10.4155/fmc-2022-0167] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]  Open
4
Thabet FM, Dawood KM, Ragab EA, Nafie MS, Abbas AA. Design and synthesis of new bis(1,2,4-triazolo[3,4-b][1,3,4]thiadiazines) and bis((quinoxalin-2-yl)phenoxy)alkanes as anti-breast cancer agents through dual PARP-1 and EGFR targets inhibition. RSC Adv 2022;12:23644-23660. [PMID: 36090415 PMCID: PMC9389373 DOI: 10.1039/d2ra03549a] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/08/2022] [Accepted: 08/10/2022] [Indexed: 12/01/2022]  Open
PrevPage 1 of 1 1Next
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA